P062 Characterization of UC1 and UC2 patients: towards personalized medicine in Ulcerative Colitis

F Castillo,K Selin,J Fransson,C Sorini,C Hedin,E Villablanca

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0192

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ulcerative colitis (UC) is a highly heterogeneous chronic inflammatory bowel disease (IBD) that primarily affects the colon. Although there are some available classifications, mostly based on clinical parameters, the lack of a molecular stratification prevents full comprehension of the diagnostic and prognostic heterogeneity of patients, and thus from correctly predicting their response to available treatments. We have recently developed an unbiased stratification of UC patients (UC1/UC2) based on their transcriptomic profiles (Czarnewski P; et al. Nature Communications, 2019), which holds great potential for the design of personalized medicine in IBD. However, further characterization is necessary to validate it and consolidate its clinical application. Methods To achieve this goal, we used bulk and single-cell RNA sequencing (sc-RNAseq) datasets from a prospective cohort of Swedish IBD patients to understand whether UC1 and UC2 are different diseases or states of the same disease, and to deeply characterize the cellular composition of UC1 and UC2 patients. In addition, we took advantage of murine spatial transcriptomics datasets of colonic tissues at steady state or during mucosal healing, to get insights into the spatiotemporal dynamics of UC1/UC2 transcriptional profiles. Results A longitudinal analysis of UC1/UC2 transcriptomic profiles as well as gene module analysis revealed that UC1 and UC2 profiles are fluctuant during the course of disease, eventually representing different stages of the same disease. scRNAseq analysis allowed us to identify specific cell types characterizing UC2 patients.[FC1] Finally, while genes defining UC2 patients distributed homogenously within the murine mouse colon at steady state and during mucosal healing, UC1 genes primarily mapped within damage/regeneration regions. Conclusion This study details the differences in immune cell composition and molecular pathways in UC1 and UC2 patients, contributing to a more comprehensive understanding of the new molecular stratification system we have developed for ulcerative colitis patients.

gastroenterology & hepatology

What problem does this paper attempt to address?

The paper aims to address the heterogeneity in diagnosis and prognosis among patients with Ulcerative Colitis (UC). Ulcerative Colitis is a highly heterogeneous chronic inflammatory bowel disease (IBD) that primarily affects the colon. Although there are currently some classification methods based on clinical parameters, the lack of molecular-level typing prevents a comprehensive understanding of the diagnostic and prognostic heterogeneity of patients, making it difficult to accurately predict patient responses to existing treatment regimens. The research team previously developed an unbiased typing system based on transcriptomic features (UC1/UC2), which holds great potential for designing personalized IBD treatment plans. However, further characterization studies are needed to validate the effectiveness of this typing system and solidify its clinical application.

Specifically, the study explores whether UC1 and UC2 represent different diseases or different states of the same disease using bulk and single-cell RNA sequencing datasets from a Swedish IBD patient cohort, and delves into the cellular composition of UC1 and UC2 patients. Additionally, spatial transcriptomics datasets from mouse colon tissues were utilized to understand the spatiotemporal dynamics of the UC1/UC2 transcriptome.

The results indicate that the UC1 and UC2 transcriptomes fluctuate during the disease process and may ultimately represent different stages of the same disease. Single-cell RNA sequencing analysis revealed that specific cell types can specifically characterize UC2 patients. Furthermore, during homeostasis and mucosal repair, genes defining UC2 patients are uniformly distributed throughout the mouse colon, whereas UC1 genes are primarily located in injury/regeneration areas.

In summary, this study provides a detailed description of the differences in immune cell composition and molecular pathways between UC1 and UC2 patients, contributing to a more comprehensive understanding of the new molecular typing system developed by researchers for Ulcerative Colitis patients.